(1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutane Hydrochloride CAS 866783-13-3 Purity >99.5% (HPLC) Ivabradine Hydrochloride Intermediate

Short Description:

Chemical Name: (1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutane Hydrochloride

CAS: 866783-13-3

Purity: >99.5% (HPLC) 

Appearance: White to Off-White Powder

Intermediate of Ivabradine Hydrochloride 

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name (1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutane Hydrochloride
Synonyms Ivabradine Hydrochloride Intermediate; (1S)-4,5-Dimethoxy-1-(Methylaminomethyl)-Benzocyclobutane HCl
CAS Number 866783-13-3
CAT Number RF-PI1811
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C12H18ClNO2
Molecular Weight 243.73
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White to Off-White Powder
Identification HPLC/UV Complies
Specific Rotation +14.0° ~ +19.0° (1% CH3OH)
Loss on Drying <0.50% (Dry it at 105℃ in vacuum till a constant weight)
Individual Impurity <0.50%
Optical Isomers <0.50%
Purity / Analysis Method >99.5% (% area normalization, by HPLC)
Assay  99.0%~100.5% (on dried basis, by Titration)
Test Standard Enterprise Standard
Usage Intermediate of Ivabradine Hydrochloride (CAS: 148849-67-6)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

(1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutane Hydrochloride (CAS: 866783-13-3) is an intermediate used in preparation of Ivabradine Hydrochloride (CAS: 148849-67-6) which is a selective bradycardic agent with direct effect on the pacemaker If current of the sinoatrial node. Ivabradine reduces the speed of diastolic depolarization and decreases heart rate. It has been approved for the treatment of chronic stable angina and provides a viable alternative to patients with a contraindication or intolerance of b-blockers. Evaluation is also underway for the potential treatment of ischemic heart disease.

  • Write your message here and send it to us